ERBB2 and breast cancer: The promoting effect of circCDYL over-expression on proliferation was partly impaired by AKT inhibitor capivasertib (0.5 μM), as detected by CCK8 experiment (Supplementary Figure 2B), indicating that circCDYL promotes proliferation of HER2– BC cells through activating of PI3K/AKT signaling pathway.